Ortanol (Omeprazole)

Omeprazole, the active ingredient in Ortanol, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal disorders in adults and adolescents.\n\nGNH India supplies Ortanol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor used to treat conditions caused by excess gastric acid.\n\nGastro‑esophageal reflux disease (GERD): reduces acid exposure and promotes healing of esophageal irritation.\nPeptic ulcer disease: facilitates ulcer healing by maintaining a higher gastric pH.\nHelicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations.\nErosive esophagitis: promotes mucosal recovery by suppressing acid secretion.

Adverse reactions may occur with any dose of omeprazole.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Diarrhea: usually transient.\n- Nausea or vomiting: occasional gastrointestinal upset.\n- Abdominal pain: cramp‑like discomfort.\n- Flatulence: increased gas production.\n- Constipation: reduced bowel movements.\n\nSerious or Rare Side Effects:\n- Severe allergic reactions: rash, swelling, or anaphylaxis.\n- Clostridioides difficile infection: persistent diarrhea with possible colitis.\n- Low magnesium levels: muscle cramps, seizures, or cardiac arrhythmia.\n- Bone fractures: increased risk with long‑term use.\n- Liver enzyme elevation: hepatitis or jaundice.

Before initiating therapy, consider the following precautions.\n\nAssess renal and hepatic function: dose adjustment may be required in severe impairment.\nMonitor for infection: prolonged acid suppression can predispose to gastrointestinal infections.\nEvaluate need for long‑term use: reassess benefits versus risks periodically.\nAvoid abrupt discontinuation: may cause rebound acid hypersecretion.\nStore at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Omeprazole may alter the pharmacokinetics of several co‑administered drugs.\n\nMajor Interactions (Avoid):\n- Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.\n- Atazanavir or other protease inhibitors: markedly decreased absorption, compromising antiviral efficacy.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: potential increase in INR, monitor coagulation parameters.\n- Methotrexate (high dose): possible accumulation, watch for toxicity.\n- Digoxin: modest increase in serum levels, consider dose adjustment.